OBJECTIVES: We examined the effect of switching to second-line antiretroviral therapy (ART) on mortality in patients who experienced immunological failure in ART programmes without access to routine viral load monitoring in sub-Saharan Africa. DESIGN AND SETTING: Collaborative analysis of two ART programmes in Lusaka, Zambia and Lilongwe, Malawi. METHODS: We included all adult patients experiencing immunological failure based on WHO criteria. We used Cox proportional hazards models weighted by the inverse probability of switching to compare mortality between patients who switched and patients who did not; and between patients who switched immediately and patients who switched later. Results are expressed as hazard ratios with 95% credible intervals (95% CI). RESULTS: Among 2411 patients with immunological failure 324 patients (13.4%) switched to second-line ART during 3932 person-years of follow-up. The median CD4 cell count at start of ART and failure was lower in patients who switched compared to patients who did not: 80 versus 155 cells/μl (P < 0.001) and 77 versus 146 cells/μl (P < 0.001), respectively. Adjusting for baseline and time-dependent confounders, mortality was lower among patients who switched compared to patients remaining on failing first-line ART: hazard ratio 0.25 (95% CI 0.09-0.72). Mortality was also lower among patients who remained on failing first-line ART for shorter periods: hazard ratio 0.70 (95% CI 0.44-1.09) per 6 months shorter exposure. CONCLUSION: In ART programmes switching patients to second-line regimens based on WHO immunological failure criteria appears to reduce mortality, with the greatest benefit in patients switching immediately after immunological failure is diagnosed.
OBJECTIVES: We examined the effect of switching to second-line antiretroviral therapy (ART) on mortality in patients who experienced immunological failure in ART programmes without access to routine viral load monitoring in sub-Saharan Africa. DESIGN AND SETTING: Collaborative analysis of two ART programmes in Lusaka, Zambia and Lilongwe, Malawi. METHODS: We included all adult patients experiencing immunological failure based on WHO criteria. We used Cox proportional hazards models weighted by the inverse probability of switching to compare mortality between patients who switched and patients who did not; and between patients who switched immediately and patients who switched later. Results are expressed as hazard ratios with 95% credible intervals (95% CI). RESULTS: Among 2411 patients with immunological failure 324 patients (13.4%) switched to second-line ART during 3932 person-years of follow-up. The median CD4 cell count at start of ART and failure was lower in patients who switched compared to patients who did not: 80 versus 155 cells/μl (P < 0.001) and 77 versus 146 cells/μl (P < 0.001), respectively. Adjusting for baseline and time-dependent confounders, mortality was lower among patients who switched compared to patients remaining on failing first-line ART: hazard ratio 0.25 (95% CI 0.09-0.72). Mortality was also lower among patients who remained on failing first-line ART for shorter periods: hazard ratio 0.70 (95% CI 0.44-1.09) per 6 months shorter exposure. CONCLUSION: In ART programmes switching patients to second-line regimens based on WHO immunological failure criteria appears to reduce mortality, with the greatest benefit in patients switching immediately after immunological failure is diagnosed.
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Jonathan A C Sterne; Miguel A Hernán; Bruno Ledergerber; Kate Tilling; Rainer Weber; Pedram Sendi; Martin Rickenbach; James M Robins; Matthias Egger Journal: Lancet Date: 2005 Jul 30-Aug 5 Impact factor: 79.321
Authors: Martin W G Brinkhof; François Dabis; Landon Myer; David R Bangsberg; Andrew Boulle; Denis Nash; Mauro Schechter; Christian Laurent; Olivia Keiser; Margaret May; Eduardo Sprinz; Matthias Egger; Xavier Anglaret Journal: Bull World Health Organ Date: 2008-07 Impact factor: 9.408
Authors: Maya L Petersen; Mark J van der Laan; Sonia Napravnik; Joseph J Eron; Richard D Moore; Steven G Deeks Journal: AIDS Date: 2008-10-18 Impact factor: 4.177
Authors: Jason D Goldman; Ronald A Cantrell; Lloyd B Mulenga; Bushimbwa C Tambatamba; Stewart E Reid; Jens W Levy; Mohammed Limbada; Angela Taylor; Michael S Saag; Sten H Vermund; Jeffrey S A Stringer; Benjamin H Chi Journal: AIDS Res Hum Retroviruses Date: 2008-08 Impact factor: 2.205
Authors: Olivia Keiser; Catherine Orrell; Matthias Egger; Robin Wood; Martin W G Brinkhof; Hansjakob Furrer; Gilles van Cutsem; Bruno Ledergerber; Andrew Boulle Journal: PLoS Med Date: 2008-07-08 Impact factor: 11.069
Authors: S E Rutstein; C E Golin; S B Wheeler; D Kamwendo; M C Hosseinipour; M Weinberger; W C Miller; A K Biddle; A Soko; M Mkandawire; R Mwenda; A Sarr; S Gupta; R Mataya Journal: AIDS Care Date: 2015-08-17
Authors: Yiping Li; Qinjian Wang; Shu Liang; Dan Yuan; Shujuan Yang; Chuanteng Feng; Hong Yang; Hang Yu Journal: JMIR Public Health Surveill Date: 2022-06-24
Authors: Maya L Petersen; Linh Tran; Elvin H Geng; Steven J Reynolds; Andrew Kambugu; Robin Wood; David R Bangsberg; Constantin T Yiannoutsos; Steven G Deeks; Jeffrey N Martin Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: Macarthur Charles; Paul D Leger; Patrice Severe; Colette Guiteau; Alexandra Apollon; Roy M Gulick; Warren D Johnson; Jean W Pape; Daniel W Fitzgerald Journal: J Int AIDS Soc Date: 2012-06-14 Impact factor: 5.396
Authors: Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771